Geode Capital Management LLC Has $41.01 Million Position in 10x Genomics, Inc. (NASDAQ:TXG)

Geode Capital Management LLC lifted its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 2.4% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 1,815,710 shares of the company’s stock after buying an additional 42,777 shares during the quarter. Geode Capital Management LLC’s holdings in 10x Genomics were worth $41,009,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. M&T Bank Corp acquired a new stake in 10x Genomics during the 3rd quarter worth approximately $203,000. Barclays PLC increased its position in 10x Genomics by 11.7% during the 3rd quarter. Barclays PLC now owns 602,536 shares of the company’s stock worth $13,605,000 after buying an additional 63,079 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in shares of 10x Genomics during the third quarter worth $402,000. XTX Topco Ltd boosted its position in shares of 10x Genomics by 241.9% in the third quarter. XTX Topco Ltd now owns 45,008 shares of the company’s stock valued at $1,016,000 after acquiring an additional 31,844 shares during the period. Finally, Weiss Asset Management LP bought a new position in 10x Genomics during the third quarter worth about $1,039,000. Institutional investors and hedge funds own 84.68% of the company’s stock.

10x Genomics Stock Performance

Shares of NASDAQ:TXG opened at $14.67 on Wednesday. 10x Genomics, Inc. has a 52-week low of $12.95 and a 52-week high of $57.78. The company has a market capitalization of $1.78 billion, a PE ratio of -9.59 and a beta of 1.84. The company has a fifty day moving average of $15.26 and a 200-day moving average of $18.61.

10x Genomics (NASDAQ:TXG) last posted its earnings results on Tuesday, October 29th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.04. The firm had revenue of $151.65 million during the quarter, compared to the consensus estimate of $158.84 million. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The business’s quarterly revenue was down 1.3% on a year-over-year basis. During the same period last year, the company earned ($0.51) earnings per share. On average, equities analysts forecast that 10x Genomics, Inc. will post -1.4 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on TXG. Canaccord Genuity Group cut their price objective on shares of 10x Genomics from $32.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, October 10th. Leerink Partners began coverage on 10x Genomics in a research report on Tuesday, September 3rd. They set an “outperform” rating and a $35.00 price target on the stock. Stephens reaffirmed an “overweight” rating and issued a $30.00 price objective on shares of 10x Genomics in a report on Thursday, October 10th. Citigroup reduced their target price on 10x Genomics from $35.00 to $23.00 and set a “buy” rating on the stock in a report on Wednesday, October 30th. Finally, The Goldman Sachs Group dropped their price target on 10x Genomics from $16.00 to $14.00 and set a “sell” rating for the company in a research note on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.14.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.